📊 NNVC Key Takeaways
Is Nanoviricides, Inc.. (NNVC) a Good Investment?
Nanoviricides is a pre-revenue pharmaceutical company with severe operational challenges, burning cash at an unsustainable rate while generating zero revenue. With only 5.2M in cash, negative operating cash flow of -3.6M annually, and no near-term revenue generation, the company faces critical liquidity risk within 12-18 months absent major financing or operational breakthroughs.
NanoViricides is pre-revenue with persistent operating losses and negative ROE/ROA, indicating no current path to profitability. Liquidity is solid and liabilities are modest, but the cash burn and negative interest coverage point to a limited runway and likely need for additional financing. Without clear progress toward revenue generation or non-dilutive funding, fundamentals remain unfavorable.
Why Buy Nanoviricides, Inc.. Stock? NNVC Key Strengths
- Strong current ratio of 4.43x provides short-term liquidity cushion
- Moderate debt-to-equity ratio of 0.43x shows conservative leverage
- Stockholders equity of 11.1M exceeds total liabilities indicating some balance sheet stability
- Strong liquidity with high current and quick ratios (4.43x)
- Low liabilities relative to assets and equity base
- Asset-light profile with minimal capex requirements
NNVC Stock Risks: Nanoviricides, Inc.. Investment Risks
- Zero revenue generation with no apparent commercialized products in market
- Negative operating cash flow of -3.6M with only 5.2M cash reserves creates critical runway concern
- Persistent operating losses of -4.0M and ROE of -36.2% indicate fundamental business viability questions
- No insider buying activity in 90 days suggests lack of management confidence
- Long-term debt of 4.7M combined with cash burn creates refinancing risk
- No revenue and ongoing operating losses (pre-revenue risk)
- Cash burn drives limited runway and potential dilution
- Debt present with negative interest coverage indicating servicing risk
Key Metrics to Watch
- Cash burn rate and remaining runway to profitability or capital raise
- Revenue recognition or pipeline advancement in clinical development
- Operating cash flow trajectory and quarterly burn trends
- Debt maturity schedule and refinancing capacity
- Insider trading activity as indicator of management confidence
- Operating cash burn (OCF/FCF trend)
- Cash and equivalents (runway in months)
Nanoviricides, Inc.. (NNVC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.43x current ratio provides a solid financial cushion.
NNVC Profit Margin, ROE & Profitability Analysis
NNVC vs Healthcare Sector: How Nanoviricides, Inc.. Compares
How Nanoviricides, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nanoviricides, Inc.. Stock Overvalued? NNVC Valuation Analysis 2026
Based on fundamental analysis, Nanoviricides, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nanoviricides, Inc.. Balance Sheet: NNVC Debt, Cash & Liquidity
NNVC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nanoviricides, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.70 indicates the company is currently unprofitable.
NNVC Revenue Growth, EPS Growth & YoY Performance
NNVC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | N/A | -$1.8M | $-0.11 |
| Q1 2026 | N/A | -$1.8M | $-0.10 |
| Q3 2025 | N/A | -$1.9M | $-0.14 |
| Q2 2025 | N/A | -$2.0M | $-0.14 |
| Q1 2025 | N/A | -$2.0M | $-0.17 |
| Q3 2024 | N/A | -$1.6M | $-0.15 |
| Q2 2024 | N/A | -$1.6M | $-0.15 |
| Q1 2024 | N/A | -$1.6M | $-0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nanoviricides, Inc.. Dividends, Buybacks & Capital Allocation
NNVC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nanoviricides, Inc.. (CIK: 0001379006)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NNVC
What is the AI rating for NNVC?
Nanoviricides, Inc.. (NNVC) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NNVC's key strengths?
Claude: Strong current ratio of 4.43x provides short-term liquidity cushion. Moderate debt-to-equity ratio of 0.43x shows conservative leverage. ChatGPT: Strong liquidity with high current and quick ratios (4.43x). Low liabilities relative to assets and equity base.
What are the risks of investing in NNVC?
Claude: Zero revenue generation with no apparent commercialized products in market. Negative operating cash flow of -3.6M with only 5.2M cash reserves creates critical runway concern. ChatGPT: No revenue and ongoing operating losses (pre-revenue risk). Cash burn drives limited runway and potential dilution.
What is NNVC's revenue and growth?
Nanoviricides, Inc.. reported revenue of $0.0.
Does NNVC pay dividends?
Nanoviricides, Inc.. does not currently pay dividends.
Where can I find NNVC SEC filings?
Official SEC filings for Nanoviricides, Inc.. (CIK: 0001379006) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NNVC's EPS?
Nanoviricides, Inc.. has a diluted EPS of $-0.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NNVC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Nanoviricides, Inc.. has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NNVC stock overvalued or undervalued?
Valuation metrics for NNVC: ROE of -36.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NNVC stock in 2026?
Our dual AI analysis gives Nanoviricides, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NNVC's free cash flow?
Nanoviricides, Inc..'s operating cash flow is $-3.6M, with capital expenditures of $84.3K.
How does NNVC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -36.2% (avg: 15%), current ratio 4.43 (avg: 2).